Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Dowpharma Signs Drug Technology Deals

March 5, 2007 | A version of this story appeared in Volume 85, Issue 10

Merck and Serum Institute of India have separately licensed Dowpharma's Pfenex technology, a Pseudomonas fluorescens-based fermentation method for making proteins. Dowpharma has developed a high-yielding strain that Merck will use to produce a protein vaccine component. The agreement with Merck also covers other proteins for use in human medicines. Meanwhile, Serum Institute will use the technology to produce an unspecified protein for its vaccine products.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.